Trial Offers Promise for Aging-Related Muscle Decline
A phase 2 research trial offers promise that decline in aging-associated muscle mass could be treated with a myostatin antibody. In the study, injections of an antibody made over a period of 24 weeks resulted in increased lean muscle mass in patients age 75 and over who had low muscle strength and performance and a history of falls.
Notes Dr. Stuart Warden, a member of the trial’s research team and an associate professor in the School of Health and Rehabilitation Sciences at Indiana University-Purdue University Indianapolis, “Myostatin is a natural protein produced within the body that inhibits muscle growth. It has been hypothesized for some time that inhibition of myostatin may allow muscle to grow, resulting in improved muscle mass and physical performance. The current study confirms these beliefs.” Learn more here.